Equities

Anika Therapeutics Inc

Anika Therapeutics Inc

Actions
  • Price (EUR)16.10
  • Today's Change0.300 / 1.90%
  • Shares traded3.00
  • 1 Year change-14.81%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 07:05 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments738694
Total Receivables, Net363530
Total Inventory464036
Prepaid expenses8.108.838.29
Other current assets, total------
Total current assets163170169
Property, plant & equipment, net757969
Goodwill, net7.577.347.78
Intangibles, net4.637582
Long term investments------
Note receivable - long term------
Other long term assets191720
Total assets271349348
LIABILITIES
Accounts payable9.869.077.63
Accrued expenses201818
Notes payable/short-term debt000
Current portion long-term debt/capital leases--00.19
Other current liabilities, total1.240.814.32
Total current liabilities312830
Total long term debt000
Total debt000.19
Deferred income tax06.4410
Minority interest------
Other liabilities, total272920
Total liabilities586460
SHAREHOLDERS EQUITY
Common stock0.150.150.14
Additional paid-in capital908167
Retained earnings (accumulated deficit)128211226
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(5.94)(6.44)(5.72)
Total equity212286287
Total liabilities & shareholders' equity271349348
Total common shares outstanding151514
Treasury shares - common primary issue0.1900
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.